MedPath

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

Ownership
-
Established
2000-10-16
Employees
795
Market Cap
-
Website
www.nkf-pharma.com
Introduction

The company is located in Nanjing, China, and is committed to building a world-class biopharmaceutical company, building an integrated pharmaceutical internationalization platform, and becoming a bridgehead for domestic companies to enter the international market. It has a mature R&D, quality, registration, and sales team in the US, and has grown into one of the most important high-end injectable suppliers in the US at the rate of more than a dozen ANDA approvals every year. The company is a pharmaceutical enterprise integrating R&D, production and sales of pharmaceuticals. It actively lays out the fields of chemicals and biopharmaceuticals, and has established a rich product pipeline covering cardiovascular, neurological, anesthetic, antitumor preparations, surgical aids, and other high-value-added sterile injections. The company's main products, fluvirizine injections, carboplatin injections, azacitidine injections, busulfan injections, bendamustine hydrochloride for injections, melphalan hydrochloride for injections, and fluorouracil injections, etc. are anti-tumor preparations. Company honors: Jiangsu Certified Enterprise Technology Center, Jiangsu Open Economy Advanced Enterprise, Nanjing Municipal Key Agricultural Commercialization Leading Enterprise, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

28

NMPA:28

Drug Approvals

Rocuronium Bromide Injection

Product Name
罗库溴铵注射液
Approval Number
国药准字H20253447
Approval Date
Feb 25, 2025
NMPA

Rocuronium Bromide Injection

Product Name
罗库溴铵注射液
Approval Number
国药准字H20253446
Approval Date
Feb 25, 2025
NMPA

Fulvestrant Injection

Product Name
氟维司群注射液
Approval Number
国药准字H20253243
Approval Date
Jan 24, 2025
NMPA

Palonosetron Hydrochloride Injection

Product Name
盐酸帕洛诺司琼注射液
Approval Number
国药准字H20244019
Approval Date
Oct 22, 2024
NMPA

Pantoprazole sodium for injection

Product Name
注射用泮托拉唑钠
Approval Number
国药准字H20249036
Approval Date
Oct 9, 2024
NMPA

Regadenoson Injection

Product Name
瑞加诺生注射液
Approval Number
国药准字H20244139
Approval Date
Jun 25, 2024
NMPA

Voriconazole for Injection

Product Name
注射用伏立康唑
Approval Number
国药准字H20243003
Approval Date
Jan 5, 2024
NMPA

Micafungin Sodium for Injection

Product Name
注射用米卡芬净钠
Approval Number
国药准字H20234655
Approval Date
Dec 19, 2023
NMPA

Micafungin Sodium for Injection

Product Name
注射用米卡芬净钠
Approval Number
国药准字H20234654
Approval Date
Dec 19, 2023
NMPA

Enoxaparin Sodium Injection

Product Name
赛倍畅
Approval Number
国药准字H20143003
Approval Date
Sep 22, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.